Ant International Deepens Payment and Digitalisation Ecosystem with AI-Driven Embedded Finance Solutions in Year of Transformation
6.12.2024 17:00:00 CET | Business Wire | Press release
Numbers show Alipay+ expands a vibrant wallet-based payment and digitalisation space that further strengthens WorldFirst and Antom, the two business fintech services.Starting with over 11 million underserved SMEs and individuals in Southeast Asia and South Asia, the new Embedded Finance segment deepens Ant International’s ecosystem by offering a rich array of FX, treasury management, inclusive lending and other AI-powered fintech solutions to clients and partners across the other three main businesses.
With a series of organisational and strategic upgrades in 2024, Ant International, a leading global digital payment and financial technology provider, reported robust growth over the past year among all its four pillar businesses, Alipay+, Antom, WorldFirst and Embedded Finance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205425502/en/
(Graphic: Business Wire)
Alipay+ expanded its vibrant wallet-based payment and digitalisation space that further strengthens WorldFirst and Antom, the two business fintech services. The new Embedded Finance segment deepens Ant International's ecosystem by offering a rich array of FX, treasury management, inclusive lending and other AI-powered fintech solutions to clients and partners across the other three main businesses.
“2024 has been a transformative year for Ant International,” said Peng Yang, Chief Executive Officer of Ant International. “We are committed to advance inclusive growth through AI-powered innovation and collaboration on cross-border travel, trade, commerce and inclusive finance.”
Based in Singapore, Ant International provides partners across industries and markets a comprehensive range of digital payment and financial technology solutions. It is committed to driving inclusive growth through open collaboration and continuous innovation.
Among Ant International's notable progresses in 2024 so far:
Alipay+: Ant International’s cross-border mobile payment and digitalisation technology solutions.
- Alipay+ leads the industry in collaboration with 35 leading mobile payment partners, including e-wallets, banking apps and BNPL apps, etc., connecting over 90 million merchants in 66 markets to 1.6 billion user accounts. It has also formed strategic partnerships with national standardised QR schemes, such as Singapore’s SGQR, Malaysia’s PayNet, South Korea’s ZeroPay, Cambodia's KHQR, Nepal’s NepalPay QR and Sri Lanka's LankaPay.
- Among the global merchants accepting QR code payments via Alipay+, over 90% are SMEs, reflecting Ant International’s focus on inclusive digital transformation.
- Cross-border transactions of global payment partners together (excluding Alipay) via Alipay+ registered three times year-on-year increase in 2024, where Alipay maintains the leadership.
Alipay+ builds a broader digital payment and digitalisation ecosystem for other pillar businesses of Ant International.
Antom: a leading merchant payment and digitisation services provider, offering one-stop, vertical-specific digital payment solutions to merchants of all sizes.
- Total payment volume (TPV) of Antom’s direct acquiring services nearly doubled between January and November 2024 over same period of 2023.
- Antom continues to strengthen its payment processing capabilities across all payment channels. Antom’s card processing volume grew over 10 times from that of previous year, while delivering top notch authorization rates to its global enterprise merchants.
- Antom continues to launch tech-driven innovative solutions to provide more secure and efficient services at lower cost to its customers. Antom Copilot helped enhance operational efficiency for merchants by reducing the payment channel integration time from 5 to 10 days to only a few minutes. Antom EasySafePay streamlined digital wallet payments procedures, eliminating the need to redirect from merchant checkout page to the user’s wallet app, and offers full account takeover protection to wallet users, and lead to significant payment success rate increase.
WorldFirst: a one-stop digital payment and financial services platform for global businesses.
- In 2024, five years after its acquisition, WorldFirst achieved an annual TPV of US$100 billion, four times that of 2020. This marks its transformation into the world's leading one-stop digital payment and financial services platform for cross-border businesses.
- Accumulatively, WorldFirst has served more than 1 million SMEs globally, with a total TPV surpassing US$300 billion and an ever-strengthening growth momentum as it expands footprints from Asia and Europe to the rest of the world.
Under Embedded Finance, our Credit Tech and Platform Tech teams leverage cutting-edge AI and blockchain technologies to innovate secure, end-to-end embedded finance solutions to clients and partners across Alipay+, Antom and WorldFirst businesses, ranging from risk-modelling, cross-border settlement, FX and liquidity management, to credit and lending services for underserved SMEs and individuals.
- In line with G20's commitment to lower cross-border payment costs via technology innovation, Platform Tech developed a world-leading Time-Series Transformer AI FX Model to help multi-national merchants in airline, e-commerce and other sectors to improve treasury management efficiency and reduce cost. Our FX solutions predict real-time local currency needs by the hour, with an accuracy of over 90%, significantly lowering cost and uncertainty for not only our own operations but millions of merchants, including SMEs.
Through collaborative innovation with global financial institutions, we leverage blockchain technology to provide 24/7 real-time cross-border settlement serviceability to our global business and clients. In 2024, the blockchain solution supported over one third of Ant International's total processing volume.
- In 2024, leveraging AI-powered Credit Tech and Risk Tech capabilities, Ant International added to ANEXT Bank, its Singapore-based MSME-focused digital bank, a new inclusive credit service under the brand bettr. Today in emerging markets including Bangladesh and Indonesia, bettr collaborates with local fintech partners to enable over 11 million unserved micro businesses and individuals, most first-time borrowers, to acquire uncollateralized loan services based on more accurate and fairer credit ratings.
- In 2024, loans under management across Ant International's SME financing services more than doubled compared to 2023.
“In 2025, we will continue to be laser-focused on supporting SMEs across borders with AI-powered innovative and trusted payment, digitalisation, and inclusive financing solutions through expanded public- and private-sector collaboration,” said Yang.
About Ant International
Headquartered in Singapore, Ant International powers the future of global commerce with digital innovation for everyone and every business to thrive. In close collaboration with partners, we support merchants of all sizes worldwide to realize their growth aspirations through a comprehensive range of tech-driven digital payment and financial services solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205425502/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom